← back to search

Marta López‐Yurda

Dutch Cancer Society ·
Area of research
Oncology · Reproductive Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Ovarian cancer diagnosis and treatment, Melanoma and MAPK Pathways, and Cutaneous Melanoma Detection and Management.
h-index
25
citations
3,268
works
96
NIH funding
primary concept
Medicine
email

Recent publications

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2− Breast Cancer: Clinical and Circulating Tumor DNA Results
Clinical Cancer Research 2026cited by 0position: middledoi
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Nature Medicine 2024cited by 63position: middledoi
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Journal of Clinical Oncology 2024cited by 23position: middledoi
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
The Lancet Oncology 2023cited by 166position: middledoi
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
The Journal of Experimental Medicine 2023cited by 71position: middledoi
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis
Journal of Clinical Oncology 2023cited by 52position: middledoi
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study
Gynecologic Oncology 2023cited by 46position: middledoi
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
Nature Medicine 2023cited by 44position: middledoi
Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases
EBioMedicine 2021cited by 39position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Geke A.P. Hospers · University Medical Center Groningen2 papers (2023–2024)Alexander M. Menzies · Melanoma Institute Australia2 papers (2023–2024)Ellen Kapiteijn · University of Amsterdam2 papers (2023–2024)Jos H. Beijnen · University of Applied Sciences Utrecht2 papers (2023–2023)Georgina V. Long · ARC Centre of Excellence in Synthetic Biology2 papers (2023–2024)Karijn P.M. Suijkerbuijk · Utrecht University2 papers (2023–2024)Christian U. Blank · Dutch Cancer Society2 papers (2023–2024)Jan H.M. Schellens · University of Applied Sciences Utrecht1 papers (2023–2023) · 1 papers (2021–2021) · 1 papers (2023–2023)Gijs van Haaften · Utrecht University1 papers (2023–2023)Bart A. van de Wiel · Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital1 papers (2024–2024)Astrid A.M. van der Veldt · Erasmus MC1 papers (2023–2023)C. Caldas · Cancer Research UK Cambridge Center1 papers (2026–2026)Alwin D. R. Huitema · University of Applied Sciences Utrecht1 papers (2023–2023) · 1 papers (2023–2023) · 1 papers (2023–2023) · 1 papers (2026–2026)Liselot Valkenburg‐van Iersel · Maastricht University Medical Centre1 papers (2023–2023) · 1 papers (2026–2026)